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Abstract: Growth hormone insensitivity syndrome (GHI) or insulin-like growth factor-1 
(IGF-1) deficiency (IGFD) is characterized by deficit of IGF-1 production due to alteration of 
response of growth hormone (GH) receptor to GH. This syndrome is due to mutation of GH 
receptor or IGF-1 gene and patients affected showed no response to GH therapy. The only treat-
ment is recombinant IGF-1 (mecasermin), which has been available since 1986, but approved in 
the United States by the US Food and Drug Administration only in 2005 and in Europe by the 
European Medicines Agency in 2007. To date, few studies are available on long-term treatment 
with mecasermin in IGFD patients and some of them have a very small number of subjects. 
In this review we discuss briefly clinical features of severe primary IGFD, laboratory findings, 
and indications for treatment. Results of long-term therapy with rhIGF1 (mecasermin) in patients 
affected by severe primary IGFD and possible side effects are explained.
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Introduction
Growth hormone insensitivity (GHI) comprises a range of disorders characterized by 
resistance to growth hormone (GH). It is well known that insulin-like growth factor-1 
(IGF-1) plays a key role in mediating GH action on human growth.1 GHI is character-
ized by deficiency of either production or peripheral action of IGF-1 on linear growth. 
Therefore, primary GHI has also been described as IGF deficiency (IGFD).2
The only therapy to date for treatment of severe IGFD is recombinant IGF-1 (rhIGF1) 
or mecasermin (Increlex™; Tercica, Brisbane, CA, USA) which has been available 
since 1986, but was approved as an orphan drug by the US Food and Drug Administra-
tion (FDA) in 2005 and by the European Medicines Agency (EMEA) in 2007.
The initial manufacturer (Fujisawa Pharmaceuticals Corp., now Astellas Pharma 
Inc., Tokyo, Japan) had developed mecasermin in Japan and marketed it as Somazon. 
Somazon was launched in 1995 for the treatment of insulin-resistant diabetes and 
primary IGFD. Tercica acquired a worldwide license (excluding Japan) for the com-
mercialization of mecasermin in April 2005.3,4
Another recombinant form of IGF-1 was developed by Chiron Corp (Emeryville, 
CA, USA) in collaboration with Cephalon Inc. (Frazer, PA, USA) for the treatment of 
amyotrophic lateral sclerosis, but the product was abandoned by early 2000.3
The results in this review are based on data obtained by studies with mecasermin 
as available from 2005 by Tercica (Increlex™).
In this review we briefly analyze the etiology and clinical findings of severe primary 
IGFD, the role of long term therapy with rhIGF-1 and prospects for the future.Therapeutics and Clinical Risk Management 2009:5 554
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Etiology of primary IGF-1 deficiency
GHI can be divided into primary or congenital and secondary 
or acquired as described in Table 1. Secondary or acquired 
GHI is characterized by GH–IGF-1 axis dysfunction due to 
malnutrition, liver diseases, catabolic illness, or neutralizing 
antibodies to growth hormones, affecting IGF-1 production 
and action. In these conditions the GH secretion is normal 
but peripheral effects is compromised with low or very low 
levels of serum IGF-1, due to a type of GH resistance or more 
often to alteration of IGF-1 production from the liver.2,10
Otherwise, primary GHI or IGFD is due to congenital 
resistance to GH action with low or absent peripheral IGF-1.2 
This syndrome, also known as Laron syndrome, was first 
described by Laron in the late 1960s as pituitary dwarfisms 
with high serum GH.2 It is a very rare syndrome resulting 
from genetic abnormality of GH receptor, mainly occurring 
in patients with high consanguinity.2,5
Over 250 cases of defects of GH receptors (GHR) have 
been described to date and over 60 of them are due to GHR 
gene mutations affecting the capacity of the receptor of 
binding, dimerizing, migrating, or initiating postreceptor 
cascade.6 Also mutations in STAT-5b,7 IGF-1,8 that leads to 
a bioinactive IGF-1, and acid labile subunit (ALS)9 genes, 
have been reported.
Clinical characteristics 
of primary IGF-1 deficiency
Patients affected by primary GHI generally show normal–low 
birth length and weight, with progressive severe postnatal 
growth failure resulting in extremely short adult stature.2,11 
Clinical features of GH deficiency are present,1 but a more 
severe impairment in growth characterizes this syndrome. 
Final height in untreated IGFD adults is 4–10 standard 
deviation score (SDS) below the mean height.
In early childhood, affected individuals appear extremely 
short and obese with thin bones and undeveloped muscles. 
In adulthood, they usually have acromicria and dispropor-
tional upper/lower segment ratio with short limbs for the 
trunk size. These patients have characteristic midfacial 
hypoplasia with protruding forehead, saddle nose, and 
sunset look. Children and some adults, especially women, 
show a very high-pitched voice.2 In adulthood, osteoporosis 
can be present but this can be considered an artifact due to 
the small bone size in these patients. Indeed when values 
of bone density are normalized for size of the patients, the 
values becomes normal for age and sex.12,13
Genitalia are small since birth and puberty is usually 
delayed, more often in boys than in girls, with testicular 
enlargement beginning between 13 and 16 years in boys 
and menarche occurring between 13 and 15 years in 
girls. In early adulthood they do not show difficulties with 
reproduction.14
Longevity has been reported to be normal in the largest 
cohort studied to date.15–17
Laboratory findings 
of primary IGF-1 deficiency
Neonates and babies with primary IGFD suffer hypoglycemia 
that continues through childhood and young adulthood. 
Before the age of six years, children show insulin nonrespon-
siveness. The response to hypoglycemia becomes normal 
during puberty when affected subjects develop adequate 
counter-regulatory mechanisms.2,14 Some patients may expe-
rience also glucose intolerance and diabetes later in life.18
IGF-1 levels are very low or undetectable with high or 
normal GH levels. Moreover, overnight GH pulses have been 
described very high, with peak values of 200–300 ng/mL 
(µg/L). The number of GH pulses, the response to exogenous 
stimuli as arginine, insulin hypoglycemia, or suppression 
with glucose administration, somatostatin, or glucocorticoids 
are always normal.2,14,20 Despite the high GH serum level, 
these patients show normal pituitary gland size.
Serum IGF-binding protein 3 (IGFBP-3) values are 
always low.
In severely short patients with normal GH response to 
provocative test, and additionally extremely low IGF-1 and/or 
IGFBP-3, an IGF-1 generation test can be helpful to confirm 
the diagnosis of IGFD. The IGF-1 generation test assesses the 
Table 1 Etiologic classification of GH insensitivity
Primary GH insensitivity syndrome (congenital)
GH receptors defects (extracellular, transmembrane, or intracellular 
mutations)
Abnormalities of GH signal transduction (STAT5B mutations)
ALS defect
Bioinactive IGF-1
Primary defects of synthesis and action of IGF-1 (IGF-1 mutations or 
IGF-1 receptor mutations)
Secondary GH insensitivity diseases (acquired)
GH-neutralizing antibodies
Malnutrition
Liver disease
Catabolic state
Chronic inflammatory and nutritional disorders
Abbreviations: ALS, acid labile subunit; GH, growth hormone; IGF-1, insulin-like 
growth factor-1.Therapeutics and Clinical Risk Management 2009:5 555
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capacity of the liver to produce IGF-1 after administration of 
exogenous rhGH. The proposed dose of rhGH for the test is 
0.033 mg/kg/day for four consecutive days. The diagnosis 
of GHI is confirmed when there is an inadequate increment 
of IGF-1 and IGFBP-3 on the fifth day.19,21
The cut-off of post-stimulated IGF-1 for the diagnosis 
of GHI is still debated, with different authors proposing 
different cut-off points. Controversy is present in the litera-
ture regarding the appropriate dose of rhGH used in the test. 
Some authors debate that 0.033 mg/kg is too high a dose 
to identify mild GHI forms and suggested that a low-dose 
IGF-1 generation test (0.011 mg/kg of rhGH for four days) 
may be more useful in diagnosis of mild cases.22 However, 
a positive response to the test can be considered an increment 
of IGF-1 or IGFBP-3 more than twice the coefficient of 
variation of the assay used.23 The test identifies almost all 
the forms of primary GHI.
Indications for treatment 
of severe IGF-1 deficiency
In 2005, the FDA approved the use of rhIGF1 (mecasermin): 
“Long term treatment of growth failure in children with severe 
primary IGFD due to mutation of the GHR or post-GHR 
signaling pathway, and the development of GH-inactivating 
antibodies in children with GH gene deletion. Severe primary 
IGFD patients with height SDS less than or equal to -3, basal 
IGF-1 SDS less than or equal to -3, and normal or elevated 
GH concentration. These patients are not GH-deficient, and 
therefore, they cannot be expected to respond adequately 
to exogenous GH treatment. rhIGF1 is not intended for use 
in subjects with secondary forms of IGF-1 deficiency, such 
as GH deficiency, malnutrition, hypothyroidism, or chronic 
treatment with pharmacologic doses of anti-inflammatory 
steroids. Thyroid and nutritional deficiencies should be 
corrected before initiating rhIGF-1. rhIGF-1 is not a substi-
tute for GH.”17,19
In 2007, the EMEA approved the use of rhIGF1 for 
“the long term treatment of growth failure in children 
and adolescents with severe primary IGFD. Severe IGFD 
is defined by height SDS score -3; basal IGF-1 levels 
below the 2.5 percentile for age and gender; GH sufficiency; 
exclusion of secondary forms of IGFD, such as malnutrition, 
hypothyroidism, or chronic treatment with pharmacologic 
doses of anti-inflammatory steroids. Severe primary IGFD 
includes patients with mutations in the GHR, post-GHR 
signaling pathway, and IGF-1 gene defects; they are not 
GH-deficient, and therefore, they cannot be expected 
to respond adequately to exogenous GH treatment. It is 
recommended to confirm the diagnosis by conducting an 
IGF-1 generation test.”19
These conditions are very rare and can affect at most 
several hundred children worldwide.4,17,24 For this reason 
many of the definition of severe primary IGFD adopted 
till now are usually ambiguous, derived by small groups of 
patients or personal experience and can be manipulated for 
marketing purposes.
In these definitions, certain items important for evaluation 
of children with short stature are not considered, such as bone 
age, parental height, and growth velocity. In this way some 
of the diagnoses of IGFD, especially in younger children, 
can be not real because of variability and usually low levels 
of serum IGF-1 in this age. On the other hand the variability 
between laboratories in analyzing IGF-1 levels and the high 
level of post-sampling proteolysis of IGF-1 make the diag-
nosis of severe IGFD more difficult.25,26
However, it has to be considered that, when using the 
FDA and EMEA definitions of severe IGFD, there is no 
risk of not treating patients affected by the disease. Indeed, 
when using these definitions as indication for rhIGF1 
treatment, all patients affected by severe IGFD will receive 
the correct therapy.
Treatment of severe primary 
IGF-1 deficiency
The only effective treatment for primary IGFD is replacement 
therapy with rhIGF1.2 Even if the drug has been available 
since 1986, for many years its use had been very restricted 
and only a small number of patients have been treated with 
the adequate therapy.
Equimolar complex of rhIGF1 and rhIGF-binding 
protein 3 (rhIGF-1/rhIGFBP3; Mecasermin Rrinfabate, Iplex; 
Insmed, Glen Allen, VA, USA) was also approved by the 
US FDA in 2005,4,16 but was withdrawn in the US in March 
2007 due to a legal settlement and is not longer available for 
use in growth-related therapy.
Since the 1990s, clinical trials on rhIGF1 therapy in 
patients affected by confirmed or suspected GHR defects have 
been conducted. The first was in Israel where the original 
Laron dwarf was identified;27 the second in Ecuador where 
the largest cohort of GHI patients was studied;28 the third in 
Europe;29 and the fourth in North America.30,31 All of these 
studies, except for the Ecuadorian one, were uncontrolled.
All data were highly consistent with good increment of 
growth rate during the first year of treatment. Growth velocity 
increased of 4.3 cm/year in the European and North America 
studies29–31 and 5.6 cm/year in the Ecuadorian study, compared Therapeutics and Clinical Risk Management 2009:5 556
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to baseline.28 These three studies used the same amount of 
rhIGF1, with twice daily administrations. In the Israel study the 
first year growth velocity was only of 3.6 cm/year, probably 
due to the single injection of a comparable total daily dose.27
The dosage used in the different studies ranged from 
40 to 120 µg/kg twice a day in the European and Ecuadorian 
studies, to 120 µg/kg twice a day, after the first year of 
therapy, in the North America study.29–31
A modest dose-dependent effect was observed especially 
during the first year of therapy. Moreover, the growth velocity 
rate showed a progressive attenuation after the first year, 
except in the Ecuadorian study, that showed less difference 
compared to the other studies between the first and the second 
year of therapy.28
At the moment, only two studies have investigated the 
long term effect of rhIGF1 therapy in IGFD patients: one by 
the European Study Group including 33 patients treated from 
48 up to 72 months29 and another by the American Study 
Group comprising 76 patients treated up to 12 years under a 
predominantly open label design.31
In the American study, height velocity increased from 
the pretreatment mean of 2.8 cm/year to an average of 
8 cm/year in the first year. In children receiving higher 
dosage (at least 100 µg/kg twice a day) the average height 
velocity was 8.7 cm/year during the first year of therapy. 
From the second year of treatment the growth veloc-
ity greatly decelerated, although the mean growth rate 
remained significantly over the baseline growth31 (Table 2). 
The authors concluded that as the rhIGF1-treated subjects 
had grown at only near normal rates for age after the first 
year, it should be unlikely for them to reach regular adult 
height.
Moreover, children with IGFD treated with rhIGF1 in 
another study were compared with growth impairment-matched 
GH-deficient children treated with rhGH. GH-deficient 
children showed an increase in growth velocity in the first 
and second year of 40% and 50%, respectively.28 Thus, 
while growth velocity in children treated for GH deficiency 
remained constantly above the normal range, which generally 
allowed them to achieve normal adult height, this was not 
possible for IGFD patients, even when treated with a high 
dose of rhIGF1 for a long-term period.
Poor compliance to therapy in these patients has been 
reported to negatively affect treatment outcomes.28 Moreover, 
the different effect on growth rate in children with severe 
IGFD treated with rhIGF1 when compared to GH-deficient 
children treated with rhGH is likely due to the difficulty in 
replicating the physiological IGF-1 distribution and action 
with rhIGF1 treatment and to restore the direct effect of 
GH on growth and metabolism. In particular exogenous 
administration of rhIGF1 probably does not restore the local 
IGF-1 action and the paracrine effect of IGF-1 on condrocyte 
proliferation within the growth plate.32
It is worth noting that IGF-1 usually complexes with 
IGFBP-3 and ALS that depend on GH level and action. 
The subcutaneously administration of rhIGF1 does not 
correct the low circulating levels of IGFBP-3 and ALS and 
therefore the clearance of rhIGF1 is accelerated and the 
tissue distribution affected.33 Moreover, it has been described 
that prolonged administration of rhIGF1 leads to generation 
of IGFBP-3 and ALS and other binding proteins, requiring 
sometimes a reduction of rhIGF1 dosage to prevent adverse 
effects.2 The possible direct effect of GH on skeletal growth 
should also be considered. This can not be restored by admin-
istration of rhIGF1 alone.
Moreover, long-term treatment with mecasermin in 
children affected by severe primary IGFD has been reported 
to reduce adipose tissue, to improve bone density, and to 
stimulate erythropoiesis, monocyte blood counts and to 
reduce platelets to within the normal range.2,37 Furthermore 
this treatment has been reported to increase androgens in 
males and gonadotropins in adults.37
Preliminary uncontrolled studies, on treatment of IGFD 
with the complexes of IGF1/IGFBP-3 (mecasermin rinfa-
bate), showed extension of serum IGF-1 half life and nor-
malization of serum levels of IGF1, but failed to demonstrate 
an improvement in growth rate, compared to treatment with 
rhIGF1 alone.17,34
Unpublished data35 demonstrated that patients receiving 
rhIGF1/IGFBP-3 at a dose equivalent to a daily dose of 
rhIGF1 of 200 µg/kg showed an increase in height velocity 
only of 3 cm/year. Patients treated with higher dose of the 
Table 2 Results of long-term treatment with rhIGF1 on growth 
velocity in primary IGF-1 deficiency
Years of  
treatment
N 
patients
Growth velocity 
(cm/year)
1 59 8.0
2 54 5.9
3 48 5.5
4 39 4.8
5 21 4.9
6 20 5.0
7 16 4.7
8 14 4.6
Abbreviations: IGF-1, insulin-like growth factor-1; rhIGF1, recombinant IGF-1.Therapeutics and Clinical Risk Management 2009:5 557
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complex comparable to 400 µg/kg of rhIGF1 per day showed 
an increment in growth rate of 6.3 cm/year.35
These data demonstrated that large amount of rhIGF1 
are needed, when administered complexed with IGFBP-3, 
to obtain the growth response comparable to rhIGF1 alone. 
Furthermore, the effect on growth velocity rapidly dimin-
ished after the first year of treatment with progressive decre-
ment as observed for rhIGF1 alone.4,17,35
Pharmacokinetic studies demonstrated a comparable 
concentration for circulating IGF-1 with twice a day rhIGF1 
injections of 80 µg/kg and daily rhIGF1/IGFBP-3 in a 
dose either 0.5 mg/kg (equivalent to 100 µg/kg of rhIGF1) 
or 1 mg/kg (equivalent to 200 µg/kg of rhIGF1). The time of 
maximal concentration for rhIGF1 treatment alone was eight 
hours and for combination treatment was about 19 hours at 
the low dose and 15 hours at higher dose. The 24 hour area 
under the curve (AUC) was comparable between rhIGF1 
therapy and the higher combination dose, while it was less 
for the lower combination dose.34
The comparable levels of circulating IGF-1 either in 
patients treated with rhIGF1 alone or with the complex, 
may be explained by the possible binding of IGF-1 to other 
IGFBPs. Indeed, IGFBP-2 is elevated in IGFD patients and 
increases with rhIGF1 therapy.36
In summary, rhIGF1 treatment in severe primary IGFD 
patients showed a prolonged effect on growth in all studies, 
particularly in long-term studies. Even if rhIGF1 treatment 
does not allow a normal catch-up growth to IGFD patients, 
especially when compared to GH therapy in GH-deficient 
children, it allows the achievement of an adult final height 
significantly greater than that expected in the absence of 
therapy.
It is still not known if the use of different dose regimens 
of rhIGF1 or new products, or an earlier start of treatment in 
children affected by IGFD, may help in the future to improve 
the height outcome of these patients.
Adverse effects of therapy 
with rhIGF1
Different adverse effects of rhIGF1 therapy are reported. 
They are summarized in Table 3. The most common adverse 
event during treatment with rhIGF1 is hypoglycemia. While 
during GH treatment in GH-deficient patients hypoglyce-
mic episodes decrease, in primary IGFD patients they can 
increase by the beginning of treatment.
Increased episodes of  hypoglycemia can be explained by the 
fact that IGF-1 increases glucose muscle uptake and decreases 
hepatic glucose release, mimicking an insulinogenic effect.38
In the largest long-term study available to date, 
hypoglycemia occurred in 49% of treated patients.31,39 It is 
worth noting that many patients manifested hypoglycemia 
even before the beginning of treatment. In a six month 
placebo-controlled study, an incidence of hypoglycemia 
of 67% in children receiving placebo was demonstrated 
versus 86% in children receiving rhIGF1 (the difference was 
not statistically significant).40 Younger subjects are usually 
more prone to develop hypoglycemia, especially when 
they are severely short with prior history of spontaneous 
hypoglycemia.31
Monitoring of blood glucose concentration by finger stick 
blood in 23 subjects residing in a research unit documented 
frequent hypoglycemia before breakfast and lunch before 
the beginning of rhIGF1 therapy. There was no increase of 
episodes of  glycemic levels under 50 mg/dl after the initiation 
of treatment. Five subjects in a crossover placebo-controlled 
study were monitored three times a day for 15 months. The 
percentage of glucose levels under 50 mg/dl was 2.6% 
in placebo versus 5.5% in rhIGF1 patients (the difference 
was not statistically significant).31,39
Hypoglycemia seems to be less frequent in patients 
treated with combination of rhIGF1/rhIGFBP-3 with a 
reported frequency of 31%.35 It seems reasonable that hypo-
glycemia can be easily controlled with adequate food intake 
before the rhIGF1 administration.
Lipohypertrophy at the site of  injection is another common 
side adverse effect. It can decrease the effect of treatment and 
it is usually due to failure of rotation of injection sites.31 Hair 
growth at the injection site for rhIGF1/IGFBP-3 combination 
Table 3 Common adverse events reported during long-term 
treatment with rhIGF1 in primary IGF-1 deficiency
Adverse events   %
Hypoglycemia 49
Hypoglycemic seizure 5
Hypoacusisa 22
Snoring 22
Tonsillar/adenoid hypertrophy 22
Tympanostomy tube placement 16
Sleep apnea 4
Tonsillectomy/adenoidectomy 11
Thymic hypertrophy 35
Lipohypertrophy 32
Orthopedic events 20
intracranial hypertension 4
Nephrolithiasis   3
Abbreviations: IGF-1, insulin-like growth factor-1; rhIGF1, recombinant IGF-1.Therapeutics and Clinical Risk Management 2009:5 558
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treatment and tachycardia for the inotropic effect of rhIGF1 
are other adverse events described.41
Intracranial hypertension or papilledema have been 
described in about 5% of patients receiving mecasermin. 
Headache was more frequent.
Lymphoid tissue hypertrophy associated sometimes with 
partial hearing loss and snoring can occur in about 22% of 
patients. In 10% of these children tonsil/adenoid hypertrophy 
may require surgical intervention. Thymic enlargement is a 
common feature during rhIGF1 treatment, occurring in about 
35% of subjects.
Some of the side effects may develop or increase during 
long-term treatment, ie, snoring was described as increasing 
from 4% during the first year of treatment to 65% in patients 
treated for longer periods.31
Acromegaloid features have also been reported in patients, 
especially those receiving mecasermin during puberty.31,39
Increase in body mass index (BMI) during treatment and 
in some case worsening of obesity has been described.29 It seems 
that in IGFD-treated children, the increase in BMI is due mainly to 
increase of fat mass, rather than increase of lean mass.2
The development of anti-IGF-1 antibodies during the 
therapy with rhIGF1 has been described. In the Chernausek 
study,31 14 out of 23 patients monitored showed positive 
anti-IGF-1 antibodies. No patients with positive antibodies 
showed statistically different growth rate compared 
to antibodies-negative patients during the first year of 
treatment.
The long-term influence of rhIGF1 therapy on cancer 
risk is still unknown. Moreover, the well known mitogenic 
effect of IGF-1 and the increased risk of neoplasia in subjects 
with elevated GH levels must be taken into account.42,43 
Furthermore, aberrant tissue development in patients 
receiving rhIGF1 has been described. For all these reasons 
caution and long-term follow up is needed in IGFD children 
treated with mecasermin.
Conclusion
The availability of rhIGF1 for treatment of  severe primary 
IGFD had improved the possibility for subjects affected by this 
rare condition to achieve higher adult height and to improve 
the outcomes of some of the clinical features of this syndrome.
Efficacy of rhIGF1 (mecasermin) therapy is not compa-
rable to GH treatment in GHD children, with still poor results 
on final adult height. This may be due to our incomplete 
knowledge of the IGFD syndrome.
The new compound, the IGF1/IGFBP-3 (mecasermin 
rinfabate) has been used to improve the effect of rhIGF1 
alone, but is no longer available due to the outcome of legal 
action in 2007.
To date the approved indication from FDA and EMEA 
for the use of mecasermin is severe short stature with very 
low IGF-1 levels and normal serum levels of GH or pres-
ence of GH antibodies. There is still no approval of rhIGF1 
therapy for the treatment of children with failure of height 
gain with rhGH therapy.
rhIGF1 can not be a substitute for GH treatment in 
GH-deficient individuals. Mecasermin has not been approved 
yet for treatment of secondary forms of IGFD such as 
malnutrition, liver dysfunction, etc.
The very recent use of mecasermin for treatment of severe 
primary IGFD, the lack of long-term data and the possible 
new adverse events indicate the need of careful use of this 
drug for other indications. Many studies are ongoing at the 
moment to understand a better classification of IGFD, the 
possible utility of IGF-1 and IGFBP-3 generation test and 
the utility of combined therapy with rhGH and rhIGF1.
In the future, new indications for the use of rhIGF1 may 
be available and alternative uses in pathologies other than 
short stature and IGFD will have to be explored.
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